Nuvera Biosciences Licenses PGx Assays to Veridex | GenomeWeb

NEW YORK (GenomeWeb News) – Nuvera Biosciences has licensed pharmacogenomic assays that it has developed to Veridex, which will commercialize the tests.

The multi-gene assays were developed for predicting patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer. Woburn, Mass.-based Nuvera developed the assays in collaboration with the University of Texas MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.